Business
Firefly Neuroscience Forms Strategic Partnership with Neurology Consultants of Dallas (NCD) to Enhance Early Detection Efforts and Disease Management for Patients with Cognitive Disorders
NCD Will Integrate Firefly’s BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes TORONTO,
About this update from Firefly Neuroscience, Inc.
[{"type":"text","content":"NCD Will Integrate Firefly’s BNA Technology into its Patient Management Protocols for Enhanced Brain Function Insights and Improved Patient Outcomes\nTORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative neuroscientific solutions that improve brain health outcomes for patients with mental illnesses and neurological disorders, today announced that it has formed a strategic partnership with the Neurology Consultants of Dallas (“NCD”) to help enhance early detection efforts and disease management for patients suffering from cognitive decline. NCD will incorporate Firefly’s Brain Network Analytics (“BNA”) technology into its patient workflow and conduct clinical studies aimed at identifying biomarkers for predicting the onset of dementia that can potentially optimize patient care pathways. \"NCD has been at the forefront of neurological care since the 1970s, providing inpatient and outpatient services. Its expertise and dedication to improving patient outcomes makes NCD an ideal partner for Firefly,” said Jon Olsen, Firefly’s CEO. \"We look forward to continuing to update our BNA technology with real patient use cases and feedback to better serve those suffering from cognitive decline and other neurological disorders across the U.S.\" \"Our integration of Firefly's BNA technology highlights the clinical value of the platform, providing diagnostic insights and trending analysis of cognitive health in conditions such as Alzheimer's disease, Parkinson’s disease, epilepsy, multiple sclerosis, concussions, and general aging,\" added Dr. Puneet Gupta, NCD's VP Health Innovation Strategy and Ventures. \"Incorporating BNA into our serial cognitive exams allows for a more comprehensive understanding of patients' brain function and cognitive health over time.\" By establishing a baseline for every patient, healthcare providers can more accurately track cognitive changes, which will promote the early detection and effective management of cognitive decline. The integration of BNA technology is expected to enhance neurology testing for millions of patients in the U.S. by encouraging widespread adoption of advanced diagnostic tools. Dr. Anna Tseng, NCD’s Chief Development Officer, concluded, “Recently, NCD...